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Colon cancer develops from the accumulation of DNA mutations and epigenetic changes that alter 
the expression or function of oncogenes and tumor-suppressor genes. A common epigenetic change 
found in cancer is aberrant DNA methylation, a biochemical change in the DNA of gene promoters 
that silences the expression of genes. High-throughput assays have uncovered multiple DNA 
mutations and DNA methylation changes throughout colon cancer genomes. However, not all of the 
changes are "drivers" that promote tumor formation, many are "passenger" changes that do not 
affect tumorigeneis. By identifying important epigenetic and genetic drivers, novel targets for 
therapeutics may be uncovered. A study led by postdoctoral fellow Dr. Yanxin Luo in the laboratory 
of Dr. William Grady used a genome-wide methylation screen to identify NTRK3 as a conditional 
tumor suppressor gene in colon cancer. 
 
NTRK3 is a member of the neurotrophin receptor family and is critical for nervous system 
development. Previously published studies suggested that NTRK3 is a dependence receptor, which 
signals in both the ligand-bound ("on") state and ligand-free ("off") state (see figure). When the 
ligand neurotrophin-3 (NT-3) is present, NTRK3 triggers signals inside the cell via a tyrosine kinase 
domain to promote cell proliferation and survival. In the absence of NT-3, NTRK3 signals for cell 
death by activating apoptosis. Therefore, NTRK3 has the potential to be either an oncogene or a 
tumor suppressor gene depending on the presence of NT-3. In breast and liver cancer, NTRK3 has 
been identified as an oncogene that promotes tumorigenesis. Conversely, DNA methylation of 
theNTRK3 promoter suggests that NTRK3 could function as a tumor suppressor in colon cancer. 
 
The Grady lab found that DNA methylation of the NTRK3 promoter occurred in tumors isolated from 
all molecular classes of colon cancer, in 67% colorectal adenocarcinomas and 60% of adenomas, 
and was not associated with other common DNA mutations.  DNA methylation of the promoter 
silenced both NTRK3 mRNA and protein expression in colon cancer cell lines and primary tumor 
samples. In addition, the expression of the ligand NT-3 was significantly lower in both colon cancer 
cell lines and primary colon cancer tissue compared to normal tissue, and was directly correlated  
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with NTRK3 expression levels. The NT-3 promoter was also methylated in select colon cancer cell 
lines and expression could be turned on with drugs that reverse DNA methylation, indicating this was 
the mechanism for reduced expression in colon cancer. 
 
In the absence of NT-3 expression, reintroducing NTRK3 expression induced cell death through 
apoptosis in colon cancer cell lines, suggesting that NTRK3 was functioning as a tumor suppressor. 
Treatment of cells with NT-3 reversed NTRK3-induced cell death, confirming that NTRK3 is a 
dependence receptor. Re-expression of NTRK3 also suppressed anchorage-independent cell 
growth of colon cancer cell lines, a hallmark of cancer in vitro, and tumor growth in vivo in a mouse 
model of colon cancer. Further supporting the notion that NTRK3 is a tumor suppressor gene, DNA 
mutations are present in the NTRK3 gene in colon, breast, lung, and liver cancer.  Luo et al. also 
found a number of mutations in NTRK3 in primary human colorectal cancers.  They expressed a 
subset of these NTRK3 mutants (G608S, I695V and L760I) in colon cancer cell lines and found that 
theNTRK3 L760I mutant inactivated the ability of NTRK3 to induce apoptosis.  The other 
mutant NTRK3 genes did not affect NTRK3 function.  These results demonstrate that both genetic 
and epigenetic mechanisms inactivate NTRK3 in colorectal cancer, and also show that some of 
the NTRK3 mutations are likely passenger mutations.   
 
According to Dr. Grady, "Our studies show that NT-3 is absent in the colon, which we argue creates 
selective pressure to inactivate NTRK3 by both genetic and epigenetic mechanisms." These results 
are similar to another study describing the role of NTRK3 in colon cancer (Genevoi et al., 2013). 
"Our findings suggest that soluble receptors for NT-3 may be an effective anti-cancer treatment. In 
addition, the high frequency of NTRK3 methylation in adenoma samples suggests that 
methylated NTRK3might be a useful biomarker for the early detection of colorectal cancer." 
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Image provided by William Grady 
The biological function of neurotrophin receptor gene 
NTRK3 depends on whether the ligand NT-3 is present. 
When NT-3 is present the tyrosine kinase receptor 
stimulates cell proliferation, while in the absence of 
ligand the NTRK3 signals for cell death. NTRK3 
functions as a tumor suppressor in colon cancer in the 
absence of NT-3. Decreased NTRK3 expression through 
DNA methylation or somatic mutations promotes colon 
tumor formation. 
 
